Treatment Options for Hyperparathyroidism

Primary Hyperparathyroidism

The American College of Radiology recommends minimally invasive parathyroidectomy (MIP) and bilateral neck exploration (BNE) as two effective surgical approaches for primary hyperparathyroidism, with MIP offering benefits of shorter operating times, faster recovery, and decreased perioperative costs compared to BNE 1, 2
MIP requires confident preoperative localization of a single parathyroid adenoma and intraoperative PTH monitoring, while BNE remains necessary for cases with discordant/nonlocalizing imaging or suspected multigland disease 1, 2

The American Journal of Kidney Diseases recommends initial treatment of secondary hyperparathyroidism with dietary phosphate restriction, phosphate binders, correction of hypocalcemia, and vitamin D sterols 3, 4
For persistent secondary hyperparathyroidism, calcimimetics (cinacalcet) may be considered, with caution due to potential hypocalcemia and increased QT interval 5, 6
Parathyroidectomy should be recommended for severe hyperparathyroidism (persistent serum levels of intact PTH >800 pg/mL) associated with hypercalcemia and/or hyperphosphatemia refractory to medical therapy, with effective surgical options including subtotal parathyroidectomy, total parathyroidectomy with parathyroid tissue autotransplantation, and total parathyroidectomy 4, 7, 8

Postoperative management should include monitoring ionized calcium every 4-6 hours for the first 48-72 hours after surgery, then twice daily until stable, with initiation of calcium gluconate infusion and adjustment of phosphate binders as needed based on serum phosphorus levels 4

Preoperative imaging with 99Tc-Sestamibi scan, ultrasound, CT scan, or MRI should be performed prior to reoperative parathyroid surgery to localize target parathyroid lesions and identify postoperative changes 1, 2, 3, 4

For persistent elevated PTH in CKD patients, the American Journal of Kidney Diseases recommends vitamin D sterols (calcitriol, paricalcitol, doxercalciferol) with dosage adjusted according to severity of hyperparathyroidism 9
For peritoneal dialysis patients, oral doses of calcitriol (0.5-1.0 μg) or doxercalciferol (2.5-5.0 μg) can be given 2-3 times weekly, as suggested by the American Journal of Kidney Diseases 9

For patients on vitamin D sterols, the American Journal of Kidney Diseases suggests monitoring serum calcium and phosphorus every 2 weeks for 1 month after initiation or dose increase, then monthly 9
For patients on vitamin D sterols, the American Journal of Kidney Diseases recommends monitoring PTH monthly for at least 3 months, then every 3 months once target levels achieved 9

Total parathyroidectomy is not recommended for patients who may subsequently receive a kidney transplant, as control of serum calcium levels may be problematic, according to the American Journal of Kidney Diseases 10